跳至主要内容
临床试验/EUCTR2011-001617-14-IT
EUCTR2011-001617-14-IT进行中(未招募)不适用

An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia

OVARTIS FARMA0 个研究点目标入组 60 人开始时间: 2012年8月10日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
OVARTIS FARMA
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Women that are 28- 33 weeks (+4 days) pregnant with a diagnosis of pre- eclampsia or superimposed pre-eclampsia requiring hospitalization - Fetus deemed in reasonably good health Other protocol-defined inclusion criteria may apply
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Severe hypertension and /or those receiving anti-hypertensive treatment at time of enrollment - Severe headaches, visual changes, or altered mentation - Upper abdominal pain, nausea, or vomiting - Low blood platelet count - Diagnosis of a seizure disorder that requires chronic medication - Those receiving active anti-coagulation therapy - Pre-gestational diabetes (Type 1 or Type 2) - Allergy to magnesium sulfate or steroids - Known major fetal anomaly - Multifetal gestation Other protocol-defined exclusion criteria may apply

研究者

发起方
OVARTIS FARMA

相似试验